GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and the oral newcomer orforglipron — are now the most widely prescribed weight-loss drugs in history. Tens of millions of people are on them. For most users, the clinical conversation has centered on weight loss, blood sugar, and cardiovascular outcomes. That conversation is now expanding.
The 2026 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS), held in April 2026, was the first major orthopedic specialty society to present dedicated research on the long-term musculoskeletal impact of GLP-1 therapy. The picture that emerged is mixed — and worth understanding if you're one of the men taking these medications.
The findings discussed here were presented at the AAOS 2026 Annual Meeting and have not yet appeared as peer-reviewed published papers at the time of writing. Conference presentations represent preliminary data — associations observed in real-world datasets. They are meaningful signals, not settled causal evidence. Interpret accordingly.
What the AAOS 2026 Research Found
The AAOS 2026 studies examined large cohorts of long-term GLP-1 users compared to matched non-users. The key musculoskeletal findings:
Associations with increased risk in long-term GLP-1 users:
- Osteoporosis — reduced bone mineral density, elevated fracture risk
- Gout — elevated uric acid crystallization and gout flare rates
- Osteomalacia — softening of bones due to impaired mineralization
On the other side of the ledger, short-term post-surgical outcomes for GLP-1 users looked notably better: lower infection rates, faster recovery, and fewer complications. This likely reflects the metabolic improvements — reduced inflammation, better glycemic control, lower body weight — that GLP-1 therapy produces in the near term.
The overall picture is a tension: better short-term surgical outcomes, but a possible signal for longer-term bone health concerns. Neither finding should be dismissed, and neither should be overstated.
The AAOS 2026 data is associational. The studies compared people who took GLP-1 drugs to people who did not — but long-term GLP-1 users differ from non-users in many ways (starting body weight, comorbidities, diet, activity level). These confounders make causal interpretation difficult. What the data shows is a signal worth monitoring, not a proven mechanism.
Why GLP-1 Therapy Might Affect Bone
There are at least three plausible biological pathways connecting GLP-1 use to bone health changes. None of them are fully confirmed in humans, but each has biological plausibility:
1. Reduced Mechanical Loading From Weight Loss
Bone is adaptive tissue. It builds and maintains density in response to mechanical stress — the forces placed on it through body weight and muscle contraction. This is why resistance training is the most reliably bone-protective intervention available, and why astronauts lose bone density in microgravity.
When someone loses 15–25% of their body weight on a GLP-1 drug, the mechanical load on their skeleton drops substantially. Less load means less stimulus for bone remodeling. Over months and years, this may translate to measurable reductions in bone mineral density — the same phenomenon seen with significant weight loss through any method, including bariatric surgery.
This mechanism suggests the bone effect may be a consequence of weight loss itself, not of GLP-1 agonism specifically.
2. Direct GLP-1 Receptor Effects on Bone Tissue
GLP-1 receptors (GLP1R) are expressed on osteoblasts (bone-building cells) and osteoclasts (bone-resorbing cells). This means the drugs you're injecting may be acting directly on bone remodeling machinery — not just on your pancreas, gut, and brain.
Animal studies have generally suggested that GLP-1 agonism at the GLP1R in bone is protective — slowing bone resorption, supporting osteoblast activity. Some observational data in humans points in the same direction. This makes the AAOS finding of increased osteoporosis risk genuinely surprising, and the mechanism genuinely unclear.
One possibility: the direct pharmacological effect on bone may be beneficial, but it's being overwhelmed by the indirect mechanical unloading effect in users who lose large amounts of weight without a compensating increase in resistance training.
3. Muscle Mass Loss Compounding the Problem
GLP-1-driven caloric restriction, if not accompanied by adequate protein intake and resistance training, can produce meaningful lean mass loss alongside fat loss. Clinical trials have shown that 25–40% of weight lost on GLP-1 agonists may come from muscle rather than fat, depending on these lifestyle factors.
Muscle loss compounds the bone loading problem: less muscle mass means less force transmitted to bone during movement, further reducing the remodeling stimulus. If you're on a GLP-1 drug and sedentary with insufficient protein intake, you may be running two bone-depleting mechanisms simultaneously.
A 2026 Nature Medicine review on the expanding landscape of GLP-1 medicines notes that research into GLP-1 receptor effects across organ systems — including bone, muscle, and the cardiovascular system — is accelerating. This is a genuinely emerging area of biology, and the clinical picture will sharpen considerably over the next few years.
What Men Using GLP-1s Should Monitor
If you're using semaglutide, tirzepatide, orforglipron, or any GLP-1 agonist, these are the bone-health variables worth tracking — and discussing with your healthcare provider. None of the following is a substitute for clinical guidance from your prescriber.
DEXA scan baseline. If you're starting a GLP-1 drug and plan to use it for more than 6 months, consider asking your provider about a baseline bone mineral density scan (DEXA). This gives you a starting point to compare against at 12 and 24 months. It's a single scan, low radiation, and takes about 10 minutes. Men over 35 or with any family history of osteoporosis have a particularly strong reason to establish a baseline.
Resistance training volume. This is the most evidence-supported bone-protective intervention available — more so than calcium supplementation alone. Compound movements (squats, deadlifts, loaded carries) create the mechanical stress that drives bone remodeling. If you're on a GLP-1 drug and not resistance training, you're leaving the most powerful bone-protection tool on the table. Track your weekly training sessions as part of your Prova protocol — consistency over time matters more than intensity.
Calcium and vitamin D adequacy. These are foundational for bone mineralization. When food intake drops significantly on a GLP-1 drug, calcium intake from dairy, leafy greens, and fortified foods often drops too. Vitamin D status affects calcium absorption. Consult your healthcare provider about whether your current intake — from diet plus supplementation — is adequate for your age and weight loss trajectory. A serum 25-OH vitamin D test is a simple starting point.
Protein intake. As covered in our guide to managing GLP-1 side effects, adequate protein is the single most important nutritional variable for lean mass preservation during GLP-1 therapy. For bone health, it matters twice: once for muscle preservation (maintaining the mechanical load on bone) and again because bone matrix itself is approximately 35% protein. Target 1.2–1.6g per kg of body weight daily, even when appetite is suppressed. Tracking daily protein in Prova through a structured 6-month experiment is one of the most actionable things you can do.
Uric acid levels. The AAOS 2026 data flagged an association between long-term GLP-1 use and elevated gout risk. If you have a family history of gout, existing elevated uric acid, or joint pain patterns consistent with gout flares, this warrants a conversation with your provider. Serum uric acid is a routine blood panel item. Log any joint symptoms in Prova to help your provider identify patterns over time.
The combination of these five variables — bone density, resistance training, calcium/vitamin D, protein, and uric acid — forms a practical bone health monitoring protocol for GLP-1 users. Run it as a structured experiment in Prova: set a 6-month timeline, log your weekly training sessions and daily protein, flag any joint symptoms, and schedule lab work at baseline, 90 days, and 6 months.
What This Doesn't Mean
Do not stop or adjust your GLP-1 prescription based on the AAOS 2026 conference findings. The cardiovascular and metabolic benefits of GLP-1 therapy — reduced risk of major adverse cardiac events, improved glycemic control, significant weight loss — are supported by large, peer-reviewed randomized controlled trials. The bone health signals from AAOS 2026 are preliminary, associational, and have not been replicated in RCTs with bone endpoints as primary outcomes. Any change to your medication should be discussed with the prescribing clinician.
A few other important framings:
The bone effects may not be GLP-1-specific. Men with obesity who lose significant weight through any means — bariatric surgery, sustained dietary intervention, intensive exercise programs — face similar mechanical unloading effects on bone. The AAOS data may be showing the consequence of significant weight loss rather than anything pharmacologically unique to GLP-1 agonism.
The AAOS data is conference-stage. These presentations have not completed peer review. The study populations, statistical adjustments, and confounders all warrant scrutiny that hasn't yet happened in publication. This is a preliminary signal, not a clinical consensus.
Proactive monitoring is the appropriate response. The case for adding bone health tracking to your GLP-1 protocol isn't that the drugs are dangerous to bone — the picture is too uncertain for that. It's that you're engaging in significant physiological change (meaningful weight loss, potential muscle changes, altered mechanical loading) and the prudent approach is to measure what's happening, not to assume everything is fine.
Understanding the GLP-1 and testosterone normalization data alongside the AAOS bone findings illustrates the broader theme: these drugs are producing systemic effects across multiple organ systems that weren't the primary focus of the original clinical trials. The science is catching up to the widespread use, and that's worth tracking.
The Tracking Protocol
If you're using a GLP-1 drug, consider adding bone health monitoring to your Prova protocol:
- Baseline: DEXA scan (if accessible), serum vitamin D, serum uric acid, body composition assessment. Log your current weekly resistance training volume and daily protein intake.
- Ongoing (weekly): Log resistance training sessions, daily protein average, any joint symptoms.
- 90 days: Repeat serum vitamin D and uric acid. Assess whether protein and training targets are being hit.
- 6 months: Repeat DEXA if baseline was done. Review the full dataset with your healthcare provider.
The goal isn't to find a problem — it's to have data if one develops. That's what structured self-tracking is for.
Be the first to try Prova
We're building an app to track whether bone-health actually works. Join the waitlist.